

HIGHMARK | HIGHMARK

MEDICAL POLICY UPDATE

March 2026

IN THIS ISSUE

Commercial Policy Changes:	1
Medicare Advantage Policy Changes:	4

Policy

This notification provides an overview of upcoming medical policy changes affecting our Commercial and Medicare Advantage lines of business. Details are outlined in the tables below.

For new policies or those with updated criteria, a direct link is provided in the title of each policy. This link will allow you to view a draft version highlighting the specific changes. Within the draft, additions to the policy are indicated by red underlined text, while deletions are shown as highlighted text with a strikethrough.

Commercial Policy Changes:

Policy Category	Policy Number and Title	Anticipated Issue Date	Impacted States
New Policy	Z-113 - Topical Oxygen Therapy	05/11/2026	All
Criteria Update	I-124 - Azacitidine (Vidaza)	05/11/2026	NY
Criteria Update	I-215 - Enfortumab vedotin-ejfv (Padcev)	05/04/2026	NY
Criteria Update	I-241 - Amivantamab-vmjw (Rybrevant) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro)	05/01/2026	PA, WV, DE
Criteria Update	I-27 - Certolizumab (Cimzia)	05/04/2026	All
Criteria Update	I-270 - Epcoritamab-bysp (Epkinyly)	05/04/2026	NY
Criteria Update	I-274 - Glofitamab-qxbm (Columvi)	05/04/2026	NY
Criteria Update	I-280 - Secukinumab (Cosentyx)	05/04/2026	All
Criteria Update	I-288 - Imetelstat (Rytelo)	05/18/2026	NY
Criteria Update	I-290 - (Tarlatamab-dlle) Imdelltra	05/18/2026	NY
Criteria Update	I-40 - Pertuzumab (Perjeta)	05/04/2026	NY
Criteria Update	I-74 - Pemetrexed (Alimta, Pemfexy)	05/11/2026	NY
Criteria Update	L-233 - Liver Fibrosis Tests	05/11/2026	NY
Criteria Update	L-294 - Genetic Testing for Bladder Cancer	06/29/2026	NY

Criteria Update	L-310 - Multitarget Polymerase Chain Reaction Testing for Diagnosis of Bacterial Vaginosis	06/01/2026	PA, WV, DE
Criteria Update	I-83 - Bortezomib (Velcade)	05/04/2026	NY
Criteria Update	M-13 - Intraoperative Neurophysiologic Monitoring (Sensory-Evoked Potentials, Motor-Evoked Potentials, EEG Monitoring)	05/04/2026	All
Criteria Update	M-18 - Cardiac Ablation Procedures	06/29/2026	All
Criteria Update	M-95 - Stress Echocardiography- Exercise or Pharmacologic	06/01/2026	PA, WV, DE
Criteria Update	M-95 - Stress Echocardiography- Exercise or Pharmacologic	06/29/2026	NY
Criteria Update	R-109 - Stereotactic Radiosurgery	05/11/2026	NY
Criteria Update	R-111 - Stereotactic Body Radiotherapy	05/11/2026	NY
Criteria Update	S-133 - Endovascular/Endoluminal Stent Grafts	06/29/2026	All
Criteria Update	S-293 - Facet Joint and Peripheral Nerve Ablation/Denervation	06/29/2026	NY
Criteria Update	S-51 - Responsive Neurostimulation for the Treatment of Refractory Partial Epilepsy	06/29/2026	All
Criteria Update	S-567 - Saphenous Vein Ablation, Radiofrequency	05/04/2026	All
Criteria Update	S-74 - Suction Assisted Lipectomy (SAL)	05/11/2026	All
Criteria Update	PA V-37 - Autism Spectrum Disorders	06/29/2026	PA
Criteria Update	DE V-37 - Autism Spectrum Disorders	06/29/2026	DE
Criteria Update	WV V-37 - Autism Spectrum Disorders	06/29/2026	WV
Criteria Update	NY V-37 - Autism Spectrum Disorders	06/29/2026	NY
Criteria Update	X-21 - Mammography	05/04/2026	All
Criteria Update	X-586 - Breast MRI	05/04/2026	All
Criteria Update	X-587 - Breast Ultrasound	05/04/2026	All
Criteria Update	Z-64 - Diagnosis and Treatment of Obstructive Sleep Apnea in Pediatric Individuals	06/01/2026	PA, WV, DE
Criteria Update	Z-64 - Diagnosis and Treatment of Obstructive Sleep Apnea in Pediatric Individuals	06/29/2026	NY
Criteria Update	Z-8 - Diagnosis and Treatment of Obstructive Sleep Apnea in Adults	05/11/2026	All
Criteria Update	Z-8 - Diagnosis and Treatment of Obstructive Sleep Apnea in Adults	05/11/2026	All
Archive	I-124 - Azacitidine (Vidaza)	05/01/2026	PA, WV, DE
Archive	I-215 - Enfortumab vedotin-ejfv (Padcev)	05/01/2026	PA, WV, DE
Archive	I-225 - Pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo)	05/01/2026	PA, WV, DE
Archive	I-260 - Tremelimumab (Imjudo)	05/01/2026	PA, WV, DE
Archive	I-262 - Teclistamab-cqyv (Tecvayli)	05/01/2026	PA, WV, DE
Archive	I-264 - Nadofaragene firadenovec-vnvcg (Adstiladrin)	05/01/2026	PA, WV, DE
Archive	I-265 - Mosunetuzumab-axgb (Lunsumio) and mosunetuzumab-axgb (Lunsumio Velo)	05/01/2026	PA, WV, DE
Archive	I-270 - Epcoritamab-bysp (Epkinly)	05/01/2026	PA, WV, DE
Archive	I-274 - Glofitamab-gxbm (Columvi)	05/01/2026	PA, WV, DE
Archive	I-293 - Denileukin diftitox-cxdl (Lymphir)	05/01/2026	PA, WV, DE
Archive	I-294 - Zanidatamab (Ziihera)	05/01/2026	PA, WV, DE
Archive	I-295 - Zolbetuximab-clzb (Vyloy)	05/01/2026	PA, WV, DE

Archive	I-36 - Palonosetron (Aloxi)	05/01/2026	PA, WV, DE
Archive	I-40 - Pertuzumab (Perjeta)	05/01/2026	PA, WV, DE
Archive	I-83 - Bortezomib (Velcade)	05/01/2026	PA, WV, DE
No Change in Coverage	I-225 - Pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo)	05/25/2026	NY
No Change in Coverage	I-228 - Lurbinectedin (Zepzelca)	05/11/2026	NY
No Change in Coverage	I-235 - Lurbinectedin (Zepzelca)	05/11/2026	NY
No Change in Coverage	I-239 - Trilaciclib (Cosela)	05/18/2026	NY
No Change in Coverage	I-241 - Amivantamab-vmjw (Rybrevant) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro)	05/25/2026	NY
No Change in Coverage	I-243 - New York Oncology Mandate	05/25/2026	NY
No Change in Coverage	I-246 - Tisotumab vendotin-tftv (Tivdak)	05/18/2026	All
No Change in Coverage	I-249 - Pennsylvania Cancer Treatment Mandate	05/25/2026	NY
No Change in Coverage	I-250 - Amivantamab-vmjw (Rybrevant) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro)	05/25/2026	NY
No Change in Coverage	I-255 - Tisotumab vendotin-tftv (Tivdak)	05/18/2026	NY
No Change in Coverage	I-260 - Tremelimumab (Imjudo)	05/11/2026	NY
No Change in Coverage	I-262 - Teclistamab-cqyv (Tecvayli)	05/11/2026	NY
No Change in Coverage	I-264 - Nadofaragene firadenovec-vncg (Adstiladrin)	05/11/2026	NY
No Change in Coverage	I-293 - Denileukin diftitox-cxdl (Lymphir)	05/25/2026	NY
No Change in Coverage	I-294 - Zanidatamab (Ziihera)	05/25/2026	NY
No Change in Coverage	I-295 - Zolbetuximab-clzb (Vyloy)	05/25/2026	NY
No Change in Coverage	I-297 - Zenocutuzumab-zbco (Bizengri)	05/25/2026	NY
No Change in Coverage	I-301 - Telisotuzumab vedotin-tllv (Emrelis)	05/25/2026	NY
No Change in Coverage	I-308 - Zenocutuzumab-zbco (Bizengri)	05/25/2026	NY
No Change in Coverage	I-311 - Telisotuzumab vedotin-tllv (Emrelis)	05/25/2026	NY
No Change in Coverage	I-52 - Palonosetron (Aloxi)	05/25/2026	NY
No Change in Coverage	L-300 - Genetic Risk Stratification for Skin Cancer	05/04/2026	NY
No Change in Coverage	L-308 - Vitamin D Testing	05/04/2026	All
No Change in Coverage	M-78 - Confocal Laser Endomicroscopy	05/04/2026	All

No Change in Coverage	R-108 – Brachytherapy	05/11/2026	NY
No Change in Coverage	R-110 - Intensity Modulated Radiation Therapy	05/11/2026	NY
No Change in Coverage	S-128 - Photodynamic Therapy with Porfimer Sodium	05/04/2026	All
No Change in Coverage	S-241 - Fecal Microbiota Transplantation	05/04/2026	All
No Change in Coverage	S-275 - Prostate Disease: Diagnosis, Staging, and Treatment	05/11/2026	All
No Change in Coverage	S-276 - Blepharoplasty, Repair of Blepharoptosis, and Repair of Brow Ptosis	05/11/2026	All
No Change in Coverage	S-277 - Laser Interstitial Thermal Therapy	05/04/2026	All
No Change in Coverage	S-346 - IVL	05/04/2026	All
No Change in Coverage	S-557 - Spider Veins, Treatment	05/04/2026	All
No Change in Coverage	Y-21 - Cognitive Rehabilitation	05/11/2026	All
No Change in Coverage	Z-100 - Deep Brain Stimulation	05/04/2026	All
No Change in Coverage	Z-46 - Blood and Bone Marrow Storage	05/11/2026	All

Medicare Advantage Policy Changes:

Policy Category	Policy Number and Title	Anticipated Issue Date	Impacted States
New Policy	X -68 - Transthoracic Echocardiography	05/04/2025	PA
New Policy	X -68 - Transthoracic Echocardiography	05/04/2025	DE
Criteria Update	I-250 - Amivantamab-vmjw (Rybrevant)	05/01/2026	All
Criteria Update	X-73 - Echocardiography	05/04/2026	WV
Archive	I-83 - Bortezomib (Velcade)	05/14/2026	All
Archive	I-52 - Palonosetron (Aloxi)	05/01/2026	All
Archive	I-115 - Pertuzumab (Perjeta)	05/01/2026	All
Archive	I-124 - Azacitidine (Vidaza)	05/01/2026	All
Archive	I-224 - Enfortumab vedotin-ejfv (Padcev)	05/01/2026	All
Archive	I-232 - Pertuzumab, trastuzumab, and hyaluronidase-zzxf (Phesgo)	05/01/2026	All
Archive	I-235 - Lurbinectedin (Zepzelca)	05/01/2026	All
Archive	I-250 - Amivantamab-vmjw (Rybrevant) and Amivantamab and hyaluronidase-lpuj (Rybrevant Faspro)	05/01/2026	All
Archive	I-255 - Tisotumab vendotin-tftv (Tivdak)	05/01/2026	All
Archive	I-271 - Tremelimumab (Imjudo)	05/01/2026	All
Archive	I-272 - Teclistamab-cqyv (Tecvayli)	05/01/2026	All
Archive	I-274 - Nadofaragene firadenovec-vncg (Adstiladrin)	05/01/2026	All

Archive	I-275 - Mosunetuzumab-axgb (Lunsumio) and mosunetuzumab-axgb (Lunsumio Velo)	05/01/2026	All
Archive	I-279 - Epcoritamab-bysp (Epkincy)	05/01/2026	All
Archive	I-283 - Glofitamab-gxbm (Columvi)	05/01/2026	All
Archive	I-298 - Imetelstat (Rytelo)	05/01/2026	All
Archive	I-300 - (Tarlataamab-dlle) Imdelltra	05/01/2026	All
Archive	I-304 - Denileukin diftitox-cxdl (Lymphir)	05/01/2026	All
Archive	I-305 - Zanidatamab (Ziihera)	05/01/2026	All
Archive	I-306 - Zolbetuximab-clzb (Vyloy)	05/01/2026	All
Archive	I-308 - Zenocutuzumab-zbco (Bizengri)	05/25/2026	All
Archive	I-311 - Telisotuzumab vedotin-tllv (Emrelis)	05/25/2026	All



Comments on These Medical Policies?

We want to know what you think about our new medical policy changes. Send us an email with any questions or comments that you may have on the new medical policies in this edition of Medical Policy Update.

Write to us at MedicalPolicyInquiries@highmarkhealth.org



eSubscribe

Subscribe to receive electronic email updates and stay informed about changes to medical policies. Sign up here: [Provider Resource Center](#)



About this Newsletter

Medical Policy Update is a monthly newsletter for the health care providers who participate in our networks and submit claims to Highmark using the appropriate HIPAA transactions or claim forms as required by Highmark. This publication focuses only on medical policy and claims administration updates, including coding guidelines and procedure code revisions, and is the sole source for this information. For all other news, information, and updates, be sure to read *Provider News*, available on the [Provider Resource Center](#).

The following entities, which serve the noted regions, are independent licensees of the Blue Cross Blue Shield Association: Western and Northeastern PA: Highmark Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Choice Company, Highmark Health Insurance Company, Highmark Coverage Advantage Inc., Highmark Benefits Group Inc., First Priority Health, First Priority Life, Highmark Care Benefits Inc., or Highmark Senior Health Company. Central and Southeastern PA: Highmark Inc. d/b/a Highmark Blue Shield, Highmark Benefits Group Inc., Highmark Health Insurance Company, Highmark Choice Company or Highmark Senior Health Company. Delaware: Highmark BCBSD Inc. d/b/a Highmark Blue Cross Blue Shield. West Virginia: Highmark West Virginia Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Health Insurance Company or Highmark Senior Solutions Company. Western NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Cross Blue Shield. Northeastern NY: Highmark Western and Northeastern New York Inc. d/b/a Highmark Blue Shield.

All references to “Highmark” in this document are references to the Highmark company that is providing the member’s health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.

Note: This publication may contain certain administrative requirements, policies, procedures, or other similar requirements of Highmark Inc. (or changes thereto) as well as interpretations of certain administrative requirements, policies and procedures (hereinafter collectively “requirements”) which are binding upon Highmark Inc. and its contracted providers. Therefore, the requirements in this publication supplement the Provider Manual. Pursuant to their contract, Highmark Inc. and such providers must comply with any requirements included herein unless and until such item(s) are subsequently modified in whole or in part.